Lunai Bioworks Approves 10:1 Reverse Stock Split

Lunai Bioworks has announced a 10:1 reverse stock split of its common stock, effective September 30, 2025. The company's board of directors has approved the move, which will result in the trading of the company's common stock on NASDAQ. This action aims to maintain the company's NASDAQ listing, which requires a minimum stock price of $1 per share.

Lunai Bioworks Inc. (NASDAQ:RENB) has announced a 10:1 reverse stock split of its common stock, effective September 30, 2025. The company's board of directors has approved the move, which will result in the trading of the company's common stock on NASDAQ under the new symbol "LNAI" with a new CUSIP number Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split^[1].

The reverse stock split aims to maintain the company's NASDAQ listing, which requires a minimum stock price of $1 per share. This action will reduce the number of outstanding shares from approximately 231.8 million to 23.2 million. The measure was approved by stockholders on August 15, 2025 Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split^[2].

The reverse stock split will convert every 10 current shares into 1 new share, with fractional shares rounded up. This adjustment is expected to increase the share price proportionally by 10x, although the company's total market capitalization will remain unchanged. The move suggests underlying valuation challenges and a defensive financial maneuver to comply with Nasdaq's minimum bid price requirement Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split^[1].

While reverse splits do not fundamentally alter company value, they often signal financial distress. Lunai Bioworks' cautionary language indicates management's uncertainty about maintaining compliance even after the split. The company's choice of the maximum authorized ratio (10:1) suggests significant concern about the current share price level Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split^[1].

The reverse stock split follows shareholder approval for a potential split ranging from 3:1 to 10:1. Management's choice of the maximum ratio indicates a high level of concern about the current share price. While maintaining NASDAQ listing preserves liquidity and institutional investor access, reverse splits historically correlate with continued downward price pressure as they do not address fundamental business challenges driving the initial share price decline Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split^[1].

Lunai Bioworks is expected to reduce the number of shares outstanding to approximately 23.2 million following the reverse stock split. The new shares will trade under the symbol "LNAI" on the Nasdaq Capital Market LLC Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split^[2].